gas

(redirected from GALNS)
Also found in: Dictionary, Medical, Legal, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • all
  • noun
  • verb

Synonyms for gas

fumes

Synonyms

petrol

Synonyms for gas

something or someone uproariously funny or absurd

to talk volubly, persistently, and usually inconsequentially

Synonyms for gas

the state of matter distinguished from the solid and liquid states by: relatively low density and viscosity

a volatile flammable mixture of hydrocarbons (hexane and heptane and octane etc.) derived from petroleum

a state of excessive gas in the alimentary canal

a fossil fuel in the gaseous state

Synonyms

Related Words

attack with gas

Related Words

References in periodicals archive ?
com/research/k78r8l/biomarins_galns) has announced the addition of the "BioMarin's GALNS - Enzyme replacement therapy for Morquio Syndrome A" report to their offering.
The method used for the synthesis of the GALNS substrate (GALNS-S) and the GALNS internal standard (GALNS-IS) has recently been described (6).
Incubation of the substrate with a DBS leads to enzymatic release of the sulfate group to produce the GALNS product (GALNS-P) (Fig.
BioMarin's Novato manufacturing facilities are also producing clinical trial material for our pipeline protein products including, GALNS for MPS IV, PEG-PAL for PKU, our CNP analog for Achondroplasia and a new biologic to be disclosed at our upcoming R&D Day.
Bienaime continued, "The facility expansion will also be the initial site of commercial production for GALNS for MPS IVA, if pivotal Phase 3 results are positive in the second half of 2012.
3Q 2011/4Q 2011: Top-line results for Phase II trial for PEG-PAL, including daily dosing and formulation studies 1Q 2012/2Q 2012: Initiation of Phase III trial for PEG-PAL 1Q 2012: Initiation of Phase I trial for BMN-111 for Achondroplasia 2H 2012: Top-line results for Phase III trial for GALNS for MPS IVA 2H 2012: Top-line results for PKU-016 Kuvan neurocognitive study 2H 2012: Top-line results for Phase I/II trial for BMN-701 for Pompe disease 4Q 2012/1Q 2013: Market authorization application filings for GALNS for MPS IVA 1Q 2013-3Q 2013: 510k clearance and commercial availability of the handheld blood Phe monitor for PKU
Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers.